VIVUS, Inc.(NASDAQ:VVUS) was another company to get an
approval from the FDA for its obesity drug Qsymia, formerly known as Qnexa.
Just three weeks ago, Arena Pharmaceuticals Inc. was the first company to won
an approval for weight loss drug.
Analysts are bullish on the prospectus of Qsymia with
analysts on Bloomberg are expecting sales to reach $1.2 billion in 2016.
The FDA rejected the name Qnexa because too many other drugs
ended in the same letters and it would have caused confusion, Vivus President
Peter Tam said.
The company may beat to market Arena Pharmaceuticals Inc.
(ARNA) (ARNA) and Eisai Co. (4523), which had their weight-loss treatment
Belviq approved by the FDA on June 27, Tam said. Vivus plans to begin selling
Qsymia -- a combination of the appetite suppressant phentermine and the
antiseizure drug topiramate -- in the fourth quarter. The Mountain View,
California-based company is building its sales capacity to market the drug
itself in the U.S., Tam said.
“We are talking to companies we believe that are capable of
supporting our product outside of the U.S.,” he said in a telephone interview.
“We are not interested in being acquired as we feel we can do a very good job
in the U.S.”
Shares of VVUS slid 7% to $24.65 in after hours following a
7.82% fall in the regular session.
No comments:
Post a Comment